Think of Sulfonylureas as CV Neutral

December 2019

New evidence will provide more reassurance about the cardiovascular safety of sulfonylureas (glimepiride, etc) for type 2 diabetes.

There's been debate for years over whether sulfonylureas increase CV risk...mainly due to data with the old, first-generation tolbutamide.

To date, all sulfonylurea med labels warn of increased CV mortality.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Pneumonia Limit Broad-Spectrum Empiric Antibiotics for Inpatient CAP Treatment
Dermatology Be Ready to Expedite Treatment for Stevens-Johnson or Other Derm Emergencies
Gastroenterology Consider More Conservative Strategies When Treating Acute Diverticulitis
Venous Thromboembolism Avoid Rivaroxaban for VTE Prophylaxis in Medical Patients
Hemorrhage Don't Focus on the INR When Treating Acute Bleeding in Cirrhosis
E-Cigarettes Use a Hospital Visit to Help E-Cig Users Stop Vaping
Seizures Consider Intranasal Midazolam Over Rectal Diazepam for Acute Seizures
Diabetes Meds Think of Sulfonylureas as CV Neutral
Contraceptives Add Vaginal Contraceptive Rings to Your Presurgical Medication Review
New Generics Watch for Confusion Between NovoLog and Its New Generics